SU-FF-J-122: Deformable Image Registration Using FDG-PET/MRI for Metastatic Breast Cancer Detection

2007 ◽  
Vol 34 (6Part6) ◽  
pp. 2396-2396
Author(s):  
T Fox ◽  
E Schreibmann ◽  
T Lauenstein ◽  
D Schuster ◽  
D Martin
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Image Registration ◽  
Cancer Detection ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
Deformable Image Registration ◽  
Breast Cancer Detection

scholarly journals Radioembolization in Metastatic Breast Cancer

2021 ◽  
Author(s):  
Amy Deipolyi ◽  
Yolanda Bryce ◽  
Ripal Gandhi
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Detection ◽  
Metastatic Breast ◽  
Breast Cancer Detection ◽  
Case Examples ◽  
Nccn Guidelines ◽  
Cancer Network ◽  
Emerging Therapy

AbstractMetastatic breast cancer (MBC) remains the second cause of cancer death in women, despite improvements in early breast cancer detection and treatments, with a 5-year survival of only 27%. Patients with MBC involving the liver have a 5-year survival of only 3.8 to 12%. Systemic therapy is the cornerstone for the treatment of MBC according to the National Comprehensive Cancer Network (NCCN) guidelines. Radioembolization is not specifically prescribed by the NCCN guidelines in the treatment of MBC liver metastasis, but is an emerging therapy with some promising results. The two primary reasons to offer radioembolization would be to prolong life and to palliate and improve quality of life. We review here the indications, contraindications, technique, case examples, and unanswered questions.

scholarly journals FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST

PLoS ONE ◽  
2018 ◽  
Vol 13 (7) ◽  
pp. e0199529 ◽  
Author(s):  
Edouard Depardon ◽  
Salim Kanoun ◽  
Olivier Humbert ◽  
Aurélie Bertaut ◽  
Jean-Marc Riedinger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Systemic Therapy ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
First Line ◽  
Pet Ct ◽  
Eortc Criteria ◽  
Prognostic Stratification ◽  
Fdg Pet Ct

18F-FDG PET/CT in a Case of Metastatic Breast Cancer to the Vulva

2019 ◽  
Vol 44 (7) ◽  
pp. 572-573
Author(s):  
Priscilla Guglielmo ◽  
Mariachiara Paderno ◽  
Federica Elisei ◽  
Luca Guerra ◽  
Claudio Landoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Prospective comparison of early interim 18F-FDG-PET with 18F-FLT-PET for predicting treatment response and survival in metastatic breast cancer

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Tzu-Pei Su ◽  
Jen-Seng Huang ◽  
Pei-Hung Chang ◽  
Kar-Wai Lui ◽  
Jason Chia-Hsun Hsieh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Clinical Response ◽  
Treatment Response ◽  
Solid Tumors ◽  
Fdg Pet ◽  
Systemic Chemotherapy ◽  
Metabolic Response ◽  
Metastatic Breast ◽  
Flt Pet

Abstract Background To compare the value of interim 18F-FLT-PET and 18F-FDG-PET for predicting treatment outcomes in patients with metastatic breast cancer after salvage therapy. Methods Patients with metastatic breast cancer received PET/CT using 18F-FLT and 18F-FDG at baseline, after the 1st and 2nd cycle of systemic chemotherapy. The clinical response was classified according to Response Evaluation Criteria in Solid Tumors 1.1 based on contrast-enhanced CT after 3 months of systemic chemotherapy. The metabolic response on PET was assessed according to European Organization for Research and Treatment of Cancer criteria or PET Response Criteria in Solid Tumors (PERCIST) and was correlated to the clinical response, overall survival (OS), and progression-free survival (PFS). Results Twenty-five patients entered final analysis. On 18F-FDG-PET, clinical responders after 2 chemotherapy cycles (post-2c) had a significantly greater reduction of maximal standardized uptake value (SUV) and the peak SUV corrected for lean body mass (SULpeak) of the tumor than non-responders (P = 0.030 and 0.003). Metabolic response determined by PERCIST on post-2c 18F-FDG-PET showed a high area under the receiver operating characteristics curve of 0.801 in predicting clinical response (P = 0.011). Patients who were metabolic responders by PERCIST on post-2c 18F-FDG-PET had a significantly longer PFS (53.8% vs. 16.7%, P = 0.014) and OS (100% vs. 47.6%, P = 0.046) than non-responders. Survival differences between responders and non-responders in the interim 18F-FLT-PET were not significant. Conclusions 18F-FLT-PET failed to show an advantage over 18F-FDG-PET in predicting the treatment response and survival in patients with metastatic breast cancer. Assessment of treatment outcome by interim 18F-FDG-PET may aid treatment. Trial registration The study was retrospectively registered on 02/06/2020 on Clinicaltrials.gov (identifier NCT04411966).

Sign in / Sign up

Export Citation Format

Share Document